Inhaled RNA Therapy Shows Promise for Reducing Lung Inflammation After Severe Infections

How Does Inhaled RNA Therapy Work to Reduce Lung Inflammation?

The inhaled RNA therapy represents a novel approach to treating post-infection lung inflammation by delivering therapeutic RNA molecules encapsulated in lipid nanoparticles directly to the respiratory tract. Unlike systemic treatments that must travel through the bloodstream, this inhalation-based delivery ensures high concentrations of the therapeutic agent reach the target tissue while minimizing systemic side effects. The lipid nanoparticle technology protects the fragile RNA molecules during delivery and facilitates their uptake by lung cells.

In preclinical models, the therapy demonstrated a meaningful reduction in key inflammatory markers in lung tissue following severe respiratory infections. The research collaboration between NTU Singapore, SUSTech, and Lipigon Pharmaceuticals leverages each institution's expertise — NTU's strength in RNA therapeutics, SUSTech's capabilities in respiratory medicine research, and Lipigon's proprietary lipid nanoparticle platform. The mechanism works by downregulating pro-inflammatory cytokine production at the gene expression level, addressing the root cause of persistent lung inflammation rather than merely suppressing symptoms.

Why Is Post-Infection Lung Inflammation Difficult to Treat?

Lung inflammation following severe respiratory infections — including influenza, bacterial pneumonia, and COVID-19 — remains a major clinical challenge. The immune system's response to serious infection can become dysregulated, leading to sustained inflammation that persists long after the pathogen has been cleared. This chronic inflammatory state contributes to fibrosis, reduced lung function, and long-term respiratory impairment. The World Health Organization has highlighted post-infectious respiratory complications as a growing concern, particularly in the wake of the COVID-19 pandemic, which left millions with lingering respiratory symptoms.

Current treatment options are limited. Systemic corticosteroids remain the standard of care for severe lung inflammation, but their long-term use is associated with immunosuppression, metabolic disruption, and increased infection risk. Targeted biologic therapies exist for conditions like severe asthma but are expensive and not specifically designed for post-infection inflammatory damage. An inhaled RNA approach could offer a precision alternative — targeting specific inflammatory pathways in the lung without the broad immunosuppressive effects of steroids. However, researchers caution that the therapy remains in early preclinical stages, and significant work is needed to establish safety and efficacy in human trials.

What Are the Next Steps Toward Clinical Application?

While the preclinical results are encouraging, the path from laboratory success to approved therapy is long and uncertain. The research team must first complete comprehensive toxicology and safety assessments to ensure the inhaled lipid nanoparticles do not cause adverse reactions in lung tissue with repeated dosing. RNA-based therapeutics have gained significant momentum since the success of mRNA COVID-19 vaccines, but inhaled delivery of RNA remains a relatively unexplored frontier with its own unique challenges, including ensuring consistent dosing and stability of the formulation.

The collaboration with Lipigon Pharmaceuticals, which specializes in lipid-based drug delivery systems, is a strategic advantage. The company's experience with lipid nanoparticle formulations could accelerate the optimization process for inhaled delivery. If preclinical safety data proves favorable, the team would need to apply for investigational new drug status before proceeding to Phase 1 human trials. Experts in pulmonary medicine have noted that direct-to-lung RNA delivery could eventually extend beyond post-infection inflammation to address other respiratory conditions, including chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis, though such applications would require their own extensive research programs.